Home
Forums
New posts
Search forums
What's new
New posts
Latest activity
Members
Current visitors
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Install the app
Install
Home
Forums
Brown Cafe Community Center
Current Events
Coronavirus
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="refineryworker05" data-source="post: 4988654" data-attributes="member: 66082"><p>Yes, they were looking at this drug back in Dec 2020, but as of right now the CDC and the FDA and the NIH say either don't take this drug(hydroxywhatever) or we can't recommend taking this drug(ivectwhatever) to treat COVID. It is insane to use the NIH as a source to support something and then reject the NIH when they say hey don't use this drug or we can't reccomend this drug for COVID right now. Smh, these posters are wrong in the exact same way on covid for over a year now. SMH.</p><p></p><p><a href="https://files.covid19treatmentguidelines.nih.gov/guidelines/covid19treatmentguidelines.pdf" target="_blank">https://files.<strong>covid19treatmentguidelines.nih.go</strong>v/guidelines/covid19treatmentguidelines.pdf</a></p><p></p><p>Antiviral Drugs That Are Approved or Under Evaluation for the Treatment of COVID-19 Last Updated: July 8, 2021 Summary Recommendations <strong><em>Remdesivir is the only Food and Drug Administration-approved drug for the treatment of COVID-19</em></strong>. In this section, the COVID-19 Treatment Guidelines Panel (the Panel) provides recommendations for using antiviral drugs to treat COVID-19 based on the available data. As in the management of any disease, treatment decisions ultimately reside with the patient and their health care provider. For more information on these antiviral agents, see Table 2e. Remdesivir • See Therapeutic Management of Hospitalized Adults with COVID-19 for recommendations on using remdesivir with or without dexamethasone. <strong><em>Ivermectin</em></strong> •<em><strong>T</strong></em><strong><em>here is insufficient evidence for the Panel to recommend either for or against the use of ivermectin for the treatment of COVID-19. Results from adequately powered, well-designed, and well-conducted clinical trials are needed to provide more specific, evidence-based guidance on the role of ivermectin in the treatment of COVID-19</em></strong>. Nitazoxanide • The Panel recommends against the use of nitazoxanide for the treatment of COVID-19, except in a clinical trial (BIIa). <strong><em>Hydroxychloroquine or Chloroquine and/or Azithromycin • The Panel recommends against the use of chloroquine or hydroxychloroquine and/or azithromycin for the treatment of COVID-19 in hospitalized patients (AI) and in nonhospitalized patients (AII</em></strong>a). Lopinavir/Ritonavir and Other HIV Protease Inhibitors • The Panel recommends against the use of lopinavir/ritonavir and other HIV protease inhibitors for the treatment of COVID-19 in hospitalized patients (AI) and in nonhospitalized patients (AIII). Rating of Recommendations: A = Strong; B = Moderate; C = Optional Rating of Evidence: I = One or more randomized trials without major limitations; IIa = Other randomized trials or subgroup analyses of randomized trials; IIb = Nonrandomized trials or observational cohort studies; III = Expert opinion</p></blockquote><p></p>
[QUOTE="refineryworker05, post: 4988654, member: 66082"] Yes, they were looking at this drug back in Dec 2020, but as of right now the CDC and the FDA and the NIH say either don't take this drug(hydroxywhatever) or we can't recommend taking this drug(ivectwhatever) to treat COVID. It is insane to use the NIH as a source to support something and then reject the NIH when they say hey don't use this drug or we can't reccomend this drug for COVID right now. Smh, these posters are wrong in the exact same way on covid for over a year now. SMH. [URL='https://files.covid19treatmentguidelines.nih.gov/guidelines/covid19treatmentguidelines.pdf']https://files.[B]covid19treatmentguidelines.nih.go[/B]v/guidelines/covid19treatmentguidelines.pdf[/URL] Antiviral Drugs That Are Approved or Under Evaluation for the Treatment of COVID-19 Last Updated: July 8, 2021 Summary Recommendations [B][I]Remdesivir is the only Food and Drug Administration-approved drug for the treatment of COVID-19[/I][/B]. In this section, the COVID-19 Treatment Guidelines Panel (the Panel) provides recommendations for using antiviral drugs to treat COVID-19 based on the available data. As in the management of any disease, treatment decisions ultimately reside with the patient and their health care provider. For more information on these antiviral agents, see Table 2e. Remdesivir • See Therapeutic Management of Hospitalized Adults with COVID-19 for recommendations on using remdesivir with or without dexamethasone. [B][I]Ivermectin[/I][/B] •[I][B]T[/B][/I][B][I]here is insufficient evidence for the Panel to recommend either for or against the use of ivermectin for the treatment of COVID-19. Results from adequately powered, well-designed, and well-conducted clinical trials are needed to provide more specific, evidence-based guidance on the role of ivermectin in the treatment of COVID-19[/I][/B]. Nitazoxanide • The Panel recommends against the use of nitazoxanide for the treatment of COVID-19, except in a clinical trial (BIIa). [B][I]Hydroxychloroquine or Chloroquine and/or Azithromycin • The Panel recommends against the use of chloroquine or hydroxychloroquine and/or azithromycin for the treatment of COVID-19 in hospitalized patients (AI) and in nonhospitalized patients (AII[/I][/B]a). Lopinavir/Ritonavir and Other HIV Protease Inhibitors • The Panel recommends against the use of lopinavir/ritonavir and other HIV protease inhibitors for the treatment of COVID-19 in hospitalized patients (AI) and in nonhospitalized patients (AIII). Rating of Recommendations: A = Strong; B = Moderate; C = Optional Rating of Evidence: I = One or more randomized trials without major limitations; IIa = Other randomized trials or subgroup analyses of randomized trials; IIb = Nonrandomized trials or observational cohort studies; III = Expert opinion [/QUOTE]
Insert quotes…
Verification
Post reply
Home
Forums
Brown Cafe Community Center
Current Events
Coronavirus
Top
